| Literature DB >> 26615100 |
Vitalijs Ovcinnikovs1, Lucy S K Walker2.
Abstract
Since the discovery of specialized T cells with regulatory function, harnessing the power of these cells to ameliorate autoimmunity has been a major goal. Here we collate the evidence that regulatory T cells (Treg) can inhibit Type 1 diabetes in animal models and humans. We discuss the anatomical sites and molecular mechanisms of Treg suppressive function in the Type 1 diabetes setting, citing evidence that Treg can function in both the pancreatic lymph nodes and within the pancreatic lesion. Involvement of the CTLA-4 pathway, as well as TGF-β and IL-2 deprivation will be considered. Finally, we summarize current efforts to manipulate Treg therapeutically in individuals with Type 1 diabetes. The translation of this research area from bench to bedside is still in its infancy, but the remarkable therapeutic potential of successfully manipulating Treg populations is clear to see.Entities:
Keywords: CTLA-4; IL-2; Immune regulation; Immunotherapy; Treg; Type 1 diabetes
Mesh:
Year: 2015 PMID: 26615100 DOI: 10.1016/bs.pmbts.2015.08.004
Source DB: PubMed Journal: Prog Mol Biol Transl Sci ISSN: 1877-1173 Impact factor: 3.622